Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe francais du myelome. N Engl J Med. 1996, 335: 91-97. 10.1056/NEJM199607113350204.
Article
CAS
PubMed
Google Scholar
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, 111: 2516-2520. 10.1182/blood-2007-10-116129.
Article
PubMed Central
CAS
PubMed
Google Scholar
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.
Article
CAS
PubMed
Google Scholar
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002, 100: 3063-3067. 10.1182/blood-2002-03-0996.
Article
CAS
PubMed
Google Scholar
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999, 341: 1565-1571. 10.1056/NEJM199911183412102.
Article
CAS
PubMed
Google Scholar
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999, 93: 55-65.
CAS
PubMed
Google Scholar
Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003, 349: 2495-2502. 10.1056/NEJMoa032290.
Article
CAS
PubMed
Google Scholar
Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009, 101: 100-106. 10.1093/jnci/djn439.
Article
CAS
PubMed
Google Scholar
Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002, 20: 1295-1303. 10.1200/JCO.20.5.1295.
Article
PubMed
Google Scholar
Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T: Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European group for blood and marrow transplantation centres. Br J Haematol. 2001, 113: 209-216. 10.1046/j.1365-2141.2001.02726.x.
Article
CAS
PubMed
Google Scholar
Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B: Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011, 118: 1979-1988. 10.1182/blood-2011-02-337329.
Article
PubMed Central
CAS
PubMed
Google Scholar
Armeson KE, Hill EG, Costa LJ: Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2012, 22964593
Google Scholar
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011, 12: 1195-1203. 10.1016/S1470-2045(11)70243-1.
Article
PubMed Central
PubMed
Google Scholar
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A: Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011, 29: 3016-3022. 10.1200/JCO.2010.32.7312.
Article
PubMed
Google Scholar
Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omede P, Baldi I: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007, 356: 1110-1120. 10.1056/NEJMoa065464.
Article
CAS
PubMed
Google Scholar
Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou R, Metzner B, Peest D, Aulitzky W, Wandt H: Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma – an interim analysis of the german DSMM V trial. Blood. 2011, 114: 51-
Google Scholar
Rosiñol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, Hernandez B, Garcia-Frade J: A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008, 112: 3591-3593. 10.1182/blood-2008-02-141598.
Article
PubMed
Google Scholar
Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, Carnevale-Schianca F, Festuccia M, Brunello L, Omede P: Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011, 117: 6721-6727. 10.1182/blood-2011-03-339945.
Article
PubMed Central
CAS
PubMed
Google Scholar
Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006, 107: 3474-3480. 10.1182/blood-2005-09-3869.
Article
CAS
PubMed
Google Scholar
Lokhorst H, Sonneveld P, Holt B, Oers M, Raymakers R, Zweegman S, Minnema M, Zijlmans M: Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/54 study. Blood. 2008, 112: 461-10.1182/blood-2007-09-077438.
Article
Google Scholar
Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol. 1998, 102: 1115-1123. 10.1046/j.1365-2141.1998.00930.x.
Article
CAS
PubMed
Google Scholar
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P: International uniform response criteria for multiple myeloma. Leukemia. 2006, 20: 1467-1473. 10.1038/sj.leu.2404284.
Article
CAS
PubMed
Google Scholar
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003, 348: 1875-1883. 10.1056/NEJMoa022340.
Article
CAS
PubMed
Google Scholar
Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D: Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol. 2007, 25: 2434-2441. 10.1200/JCO.2006.10.2509.
Article
PubMed
Google Scholar
Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW: Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the dutch cooperative group HOVON 24 trial. Haematologica. 2007, 92: 928-935. 10.3324/haematol.11168.
Article
CAS
PubMed
Google Scholar
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L: Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myelome. Blood. 2007, 109: 3489-3495. 10.1182/blood-2006-08-040410.
Article
CAS
PubMed
Google Scholar
Dispenzieri A: Is there a future for auto-allo HSCT in multiple myeloma?. Lancet Oncol. 2011, 12: 1176-1177. 10.1016/S1470-2045(11)70258-3.
Article
PubMed
Google Scholar
Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB: Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007, 82: 323-341.
Article
CAS
PubMed
Google Scholar
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA: Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009, 84: 1095-1110. 10.4065/mcp.2009.0603.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 8: 16-10.1186/1745-6215-8-16.
Article
PubMed Central
PubMed
Google Scholar
Stuart A, Ord K: Kendall′s advanced theory of statistics. 1994, Wiley
Google Scholar
Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 edition. 2011, The Cochrane Collaboration
Google Scholar
RevMan: Review Manager: The Cochrane Collaboration-available on the world wide web.http://www.cochrane.org/cochrane/revman.htm, 51st,
StatsDirect Ltd: StatsDirect statistical software. 2008, England: Stats Direct Ltd,http://www.statsdirect.com,
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009, 62: e1-34. 10.1016/j.jclinepi.2009.06.006.
Article
PubMed
Google Scholar